Targeting CD22 for the Treatment of B-Cell Malignancies

References

• Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Morrison VA, Hong F, Habermann TM, et al. R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): long-Term Follow-up of Intergroup E4494/C9793. Blood. 2010;116:589. doi:10.1182/blood.V116.21.589.589
   Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598
   PubMed Web of Science ®Google Scholar
• Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6(10):1341–1353. doi:10.1586/14737140.6.10.1341
   PubMed Web of Science ®Google Scholar
• Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):242–244. doi:10.1126/science.7618087
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood. 1999;94(4):1382–1392. doi:10.1182/blood.V94.4.1382
   Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol. 2008;26(22):3756–3762. doi:10.1200/jco.2007.15.3528
   PubMed Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children’s Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015;62(7):1171–1175. doi:10.1002/pbc.25454
   PubMed Web of Science ®Google Scholar
• Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children’s Oncology Group Study[corrected]. J Clin Oncol. 2008;26(24):3971–3978. doi:10.1200/jco.2008.16.1414
   PubMed Web of Science ®Google Scholar
• Advani AS, McDonough S, Coutre S, et al. SWOG S0910: a Phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;165(4):504–509. doi:10.1111/bjh.12778
   PubMed Web of Science ®Google Scholar
• Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010;151(5):430–434. doi:10.1111/j.1365-2141.2010.08387.x
   PubMed Web of Science ®Google Scholar
• Chevallier P, Huguet F, Raffoux E, et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica. 2015;100(4):e128–31. doi:10.3324/haematol.2014.120220
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(22):5044–5051. doi:10.1200/jco.2005.13.821
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21(16):3051–3059. doi:10.1200/jco.2003.01.082
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16):5327–5334. doi:10.1158/1078-0432.Ccr-04-0294
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24(24):3880–3886. doi:10.1200/jco.2006.05.6291
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113(10):2714–2723. doi:10.1002/cncr.23890
   PubMed Web of Science ®Google Scholar
• Micallef IN, Kahl BS, Maurer MJ, et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006;107(12):2826–2832. doi:10.1002/cncr.22342
   Web of Science ®Google Scholar
• Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053–4061. doi:10.1182/blood-2011-02-336990
   PubMed Web of Science ®Google Scholar
• Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2Pt A):107–116. doi:10.1016/j.molimm.2014.09.014
   Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, Phase 3 INO-VATE study. Cancer. 2019;125(14):2474–2487. doi:10.1002/cncr.32116
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(8):740–753. doi:10.1056/NEJMoa1509277
   PubMed Web of Science ®Google Scholar
• Jabbour E, Sasaki K, Ravandi F, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124(20):4044–4055. doi:10.1002/cncr.31720
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248. doi:10.1016/s1470-2045(18)30011-1
   PubMed Web of Science ®Google Scholar
• Martell MP, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163(4):458–464. doi:10.1111/bjh.12561
   PubMed Web of Science ®Google Scholar
• Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–2093. doi:10.1200/JCO.2009.25.1900
   PubMed Web of Science ®Google Scholar
• Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583. doi:10.1200/JCO.2012.42.7211
   PubMed Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840–1845. doi:10.1111/j.1349-7006.2010.01601.x
   PubMed Web of Science ®Google Scholar
• Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182(4):583–586. doi:10.1111/bjh.14820
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398–6405. doi:10.1158/1078-0432.Ccr-11-0487
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777. doi:10.1038/s41375-018-0210-1
   PubMed Web of Science ®Google Scholar
• Shah NN, Bhojwani D, August K, et al. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(5):e28112. doi:10.1002/pbc.28112
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Jabbour E, et al. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018;182(3):442–444. doi:10.1111/bjh.14806
   Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23(27):6719–6729. doi:10.1200/JCO.2005.11.437
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27(18):2983–2990. doi:10.1200/JCO.2008.20.2630
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241–247. doi:10.1056/NEJM200107263450402
   PubMed Web of Science ®Google Scholar
• Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85(12):3457–3465. doi:10.1182/blood.V85.12.3457.bloodjournal85123457
   PubMed Web of Science ®Google Scholar
• Bachanova V, Frankel AE, Cao Q, et al. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015;21(6):1267–1272. doi:10.1158/1078-0432.Ccr-14-2877
   PubMed Web of Science ®Google Scholar
• Chevallier P, Eugene T, Robillard N, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2(3):e108–117. doi:10.1016/s2352-3026(15)00020-4
   Google Scholar
• Morschhauser F, Kraeber-Bodéré F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28(23):3709–3716. doi:10.1200/jco.2009.27.7863
   Web of Science ®Google Scholar
• Witzig TE, Tomblyn MB, Misleh JG, et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014;99(11):1738–1745. doi:10.3324/haematol.2014.112110
   Web of Science ®Google Scholar
• Kraeber-Bodere F, Pallardy A, Maisonneuve H, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with (90) Y-epratuzumabtetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol. 2017;4(1):e35–e45. doi:10.1016/s2352-3026(16)30168-5
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19(4):769–773. doi:10.1093/annonc/mdm560
   Web of Science ®Google Scholar
• Linden O, Bates AT, Cunningham D, et al. Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: a First-in-Human, Phase I Study. Cancer Biother Radiopharm. 2021. doi:10.1089/cbr.2020.4653
   Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441
   PubMed Web of Science ®Google Scholar
• Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020;38(17):1938–1950. doi:10.1200/jco.19.03279
   PubMed Web of Science ®Google Scholar
• Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. doi:10.1186/s13045-020-00856-8
   PubMed Web of Science ®Google Scholar
• Titov A, Zmievskaya E, Ganeeva I, et al. Adoptive Immunotherapy beyond CAR T-Cells. Cancers. 2021;13(4):743. doi:10.3390/cancers13040743
   PubMed Web of Science ®Google Scholar
• Schneider D, Xiong Y, Wu D, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021;13(586):eabc6401. doi:10.1126/scitranslmed.abc6401
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar